Eye drops developed by UBC researchers could one day treat glaucoma while you sleep – helping to heal a condition that is one of the leading causes of blindness around the world.
The company behind the study hopes to complete their study evaluating the use of cannabis oil for treating chronic pain by fall 2018.
The launch of Delta™ means producers are now able to to recreate and restore the full plant terpene profile in any oil-based cannabis product.
The trial will help distinguish between multiple formulations based on various measures, including pharmacological and pharmacodynamic measures that may be predictive of drug efficacy.
A clinical trial centered at the Children’s Hospital of Philadelphia is hoping to find evidence that cannabinoids can help treat pediatric autism.
Human brain imaging clinical trials are already underway for a proprietary cannabinoid formulation to treat a major condition.
Using data provided by the Washington State Liquor and Cannabis Board researchers have highlighted inconsistencies and possible foul play across cannabis testing labs in Washington State.
The testing performed by MA Analytics will protect consumers from contaminants, chemicals, and other impurities ensuring that the end consumer is getting the best possible product.
Keystone State Testing is leading the way in PA and has also received accreditation from Americans for Safe Access.